These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36160460)

  • 21. DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients.
    Liu F; Tu Z; Liu J; Long X; Xiao B; Fang H; Huang K; Zhu X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34988580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
    Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
    Front Oncol; 2022; 12():889351. PubMed ID: 36033495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
    Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
    Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
    Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
    Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a glioma prognostic model based on telomere-related genes and immune infiltration analysis.
    Liu X; Wang J; Su D; Wang Q; Li M; Zuo Z; Han Q; Li X; Zhen F; Fan M; Chen T
    Transl Cancer Res; 2024 Jul; 13(7):3182-3199. PubMed ID: 39145097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
    Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
    Front Immunol; 2022; 13():810832. PubMed ID: 35265072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses.
    Ding M; Li YA; Lu Z; Hou G
    Biomed Res Int; 2022; 2022():1734847. PubMed ID: 35198632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
    He Y; Ye Y; Tian W; Qiu H
    Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
    [No Abstract]   [Full Text] [Related]  

  • 31. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of tryptophan metabolic gene-related subtypes, development of prognostic models, and characterization of tumor microenvironment infiltration in gliomas.
    Liu Y; Xiang J; Liao Y; Peng G; Shen C
    Front Mol Neurosci; 2022; 15():1037835. PubMed ID: 36407768
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
    Front Immunol; 2022; 13():974346. PubMed ID: 36275718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
    Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
    Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 38. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a copper metabolism-related gene signature for predicting prognosis and immune response in glioma.
    Li L; Leng W; Chen J; Li S; Lei B; Zhang H; Zhao H
    Cancer Med; 2023 Apr; 12(8):10123-10137. PubMed ID: 36856182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.